CryoLife Announces Release Date for First Quarter Revenues and Earnings And Shareholder Access to Teleconference Call Following Release of First Quarter Results

Apr 10, 2001, 01:00 ET from CryoLife, Inc.

    ATLANTA, April 10 /PRNewswire/ -- CryoLife, Inc. (NYSE:   CRY), the leader
 in the development and commercialization of tissue-engineered implantable
 heart valves, vascular grafts and protein-based adhesives, announced today
 that first quarter revenues and earnings figures would be released on
 April 17, 2001.
     The Company also announced that immediately following the release of
 financial results, an analysts' teleconference would be held promptly at
 11:15 a.m. Eastern Time hosted by Steven G. Anderson, CryoLife President and
 Chief Executive Officer.
     Shareholders interested in listening in on the teleconference may do so by
 calling (973) 321-1020 a few minutes prior to 11:15 a.m.  No identification
 number is required.  Shareholders interested in listening to a replay of the
 teleconference call may do so by calling (877) 519-4471 (toll free) or
 (973) 341-3080; the pass code for the replay is 2520407.  The replay will be
 available April 17 through April 20, 2001.
     Founded in 1984, CryoLife, Inc., is the leader in the development and
 commercialization of implantable living human tissues for use in
 cardiovascular, vascular and orthopaedic surgeries throughout the United
 States and Canada.  The Company's BioGlue(R) surgical adhesive is approved as
 an adjunct for acute thoracic aortic dissections under HDE regulations in the
 United States and is CE marked in the European Union and approved in Canada
 and Australia for use in vascular and pulmonary sealing and repair.  The
 Company also manufactures the SynerGraft(R) heart valve, the world's first
 tissue-engineered heart valve replacement and the CryoLife-O'Brien(R) and
 CryoLife-Ross(R) stentless porcine heart valves, which are CE Marked for
 distribution within the European Community.  The human heart valves and
 vascular grafts processed by CryoLife using the SynerGraft technology are
 distributed in the U.S. under the trade names of CryoValve(R)SG and
 CryoVein(R)SG, respectively.
     For additional information about the company, visit CryoLife's web site:
 http://www.cryolife.com .
 
     Contact:   D. Ashley Lee
                Vice President, Chief Financial Officer
                (800) 438-8285
 
 

SOURCE CryoLife, Inc.
    ATLANTA, April 10 /PRNewswire/ -- CryoLife, Inc. (NYSE:   CRY), the leader
 in the development and commercialization of tissue-engineered implantable
 heart valves, vascular grafts and protein-based adhesives, announced today
 that first quarter revenues and earnings figures would be released on
 April 17, 2001.
     The Company also announced that immediately following the release of
 financial results, an analysts' teleconference would be held promptly at
 11:15 a.m. Eastern Time hosted by Steven G. Anderson, CryoLife President and
 Chief Executive Officer.
     Shareholders interested in listening in on the teleconference may do so by
 calling (973) 321-1020 a few minutes prior to 11:15 a.m.  No identification
 number is required.  Shareholders interested in listening to a replay of the
 teleconference call may do so by calling (877) 519-4471 (toll free) or
 (973) 341-3080; the pass code for the replay is 2520407.  The replay will be
 available April 17 through April 20, 2001.
     Founded in 1984, CryoLife, Inc., is the leader in the development and
 commercialization of implantable living human tissues for use in
 cardiovascular, vascular and orthopaedic surgeries throughout the United
 States and Canada.  The Company's BioGlue(R) surgical adhesive is approved as
 an adjunct for acute thoracic aortic dissections under HDE regulations in the
 United States and is CE marked in the European Union and approved in Canada
 and Australia for use in vascular and pulmonary sealing and repair.  The
 Company also manufactures the SynerGraft(R) heart valve, the world's first
 tissue-engineered heart valve replacement and the CryoLife-O'Brien(R) and
 CryoLife-Ross(R) stentless porcine heart valves, which are CE Marked for
 distribution within the European Community.  The human heart valves and
 vascular grafts processed by CryoLife using the SynerGraft technology are
 distributed in the U.S. under the trade names of CryoValve(R)SG and
 CryoVein(R)SG, respectively.
     For additional information about the company, visit CryoLife's web site:
 http://www.cryolife.com .
 
     Contact:   D. Ashley Lee
                Vice President, Chief Financial Officer
                (800) 438-8285
 
 SOURCE  CryoLife, Inc.